| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Matthew C Pickering | Q55692581 |
| Richard J Smith | Q58399821 | ||
| P2093 | author name string | Claire L. Harris | |
| Claire L Harris | |||
| Matthew C. Pickering | |||
| P2860 | cites work | Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II) | Q24317382 |
| Control of the amplification convertase of complement by the plasma protein beta1H | Q24561671 | ||
| Structural basis for engagement by complement factor H of C3b on a self surface | Q24604385 | ||
| Structure of complement fragment C3b-factor H and implications for host protection by complement regulators | Q24646723 | ||
| Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice | Q24651118 | ||
| Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications | Q24681724 | ||
| Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H | Q28114862 | ||
| Dense deposit disease: a variant of membranoproliferative glomerulonephritis | Q28144476 | ||
| Complement. First of two parts | Q28210663 | ||
| Complement. Second of two parts | Q28211878 | ||
| Structure of C3b in complex with CRIg gives insights into regulation of complement activation | Q28269302 | ||
| Structure of C3b reveals conformational changes that underlie complement activity | Q28269312 | ||
| Role of vitronectin and its receptors in haemostasis and vascular remodeling | Q28272554 | ||
| Structures of complement component C3 provide insights into the function and evolution of immunity | Q28273530 | ||
| Production of biologically active recombinant human factor H in Physcomitrella | Q28290970 | ||
| An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD) | Q28293350 | ||
| Dense deposit disease is not a membranoproliferative glomerulonephritis | Q28295719 | ||
| Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase | Q41443111 | ||
| Small margin excision of periocular basal cell carcinomas | Q42451228 | ||
| Functional and morphological macular abnormalities in membranoproliferative glomerulonephritis type II. | Q42949064 | ||
| Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event | Q44437858 | ||
| Serum C'3 lytic system in patients with glomerulonephritis | Q44885697 | ||
| Hypocomplementemic glomerulonephritis in an infant and mother. Evidence for an abnormal form of C3. | Q45079393 | ||
| Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience | Q46486094 | ||
| Inherited factor H deficiency and collagen type III glomerulopathy | Q49287293 | ||
| A descriptive study of individuals with membranoproliferative glomerulonephritis. | Q51745279 | ||
| Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H | Q57089510 | ||
| H deficiency in two brothers with atypical dense intramembranous deposit disease | Q59619455 | ||
| On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production | Q67546253 | ||
| C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase | Q67740087 | ||
| Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF | Q68424301 | ||
| Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor | Q69124128 | ||
| Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis | Q70539365 | ||
| Hypocomplementaemia due to a genetic deficiency of beta 1H globulin | Q70567912 | ||
| Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor | Q72638926 | ||
| Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor | Q72834641 | ||
| In situ complement activation in porcine membranoproliferative glomerulonephritis type II | Q74165088 | ||
| Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up | Q74267577 | ||
| Factor H deficiency and fibrillary glomerulopathy | Q75434821 | ||
| Potential protective role of apoprotein J (clusterin) in atherogenesis: binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity | Q81607398 | ||
| Anti-factor B autoantibody in dense deposit disease | Q83087439 | ||
| Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation | Q84071466 | ||
| Production of biologically active complement factor H in therapeutically useful quantities | Q28300280 | ||
| Functional properties of membrane cofactor protein of complement | Q28610962 | ||
| Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome | Q33347509 | ||
| Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases | Q33359650 | ||
| Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. | Q33360768 | ||
| Complement regulators and inhibitory proteins | Q33386110 | ||
| The role of complement in AMD. | Q33391415 | ||
| Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities | Q33393852 | ||
| Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway | Q33403738 | ||
| Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice | Q34005720 | ||
| Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation | Q34162206 | ||
| Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature | Q34293159 | ||
| Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice | Q34537391 | ||
| Complement Receptor 1: disease associations and therapeutic implications. | Q34878497 | ||
| Heterogeneity of nephritic factor and its identification as an immunoglobulin | Q35052508 | ||
| Allelic variants of complement genes associated with dense deposit disease | Q35142753 | ||
| Pathogenesis of lesions in late age-related macular disease | Q35688114 | ||
| The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion | Q35748229 | ||
| Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. | Q35990700 | ||
| Membranoproliferative glomerulonephritis type II (dense deposit disease): an update | Q36084453 | ||
| Complement decay accelerating factor (DAF)/CD55 in cancer. | Q36399496 | ||
| Alternative roles for CD59. | Q36555055 | ||
| The role of CR2 in autoimmunity. | Q36572973 | ||
| Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein | Q36860930 | ||
| New approaches to the treatment of dense deposit disease | Q36860946 | ||
| Complement receptors CD21 and CD35 in humoral immunity | Q36938627 | ||
| Complement driven by conformational changes | Q37026644 | ||
| Translational mini-review series on complement factor H: structural and functional correlations for factor H. | Q37032788 | ||
| Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B | Q37132696 | ||
| A role of macrophage complement receptor CRIg in immune clearance and inflammation. | Q37254633 | ||
| Complement in human diseases: Lessons from complement deficiencies | Q37501005 | ||
| The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity | Q39968584 | ||
| Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis | Q40144637 | ||
| Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration | Q40151482 | ||
| Further evidence for the antibody nature of C3 nephritic factor (C3NeF) | Q41067359 | ||
| P433 | issue | 14 | |
| P304 | page(s) | 1604-1610 | |
| P577 | publication date | 2011-05-24 | |
| 2011-08-01 | |||
| P1433 | published in | Molecular Immunology | Q6895954 |
| P1476 | title | Dense deposit disease | |
| P478 | volume | 48 |
| Q30409539 | A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors |
| Q38232593 | An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases |
| Q38057737 | C3 glomerulonephritis and CFHR5 nephropathy |
| Q42246527 | C3 nephritic factor associated with C3 glomerulopathy in children |
| Q30274884 | C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy |
| Q35758595 | Causes of alternative pathway dysregulation in dense deposit disease |
| Q35580577 | Clinical features and outcomes of 98 children and adults with dense deposit disease. |
| Q35246525 | Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience |
| Q30415634 | Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis |
| Q26829790 | Complement cascade and kidney transplantation: The rediscovery of an ancient enemy |
| Q40986583 | Complement in Non-Antibody-Mediated Kidney Diseases. |
| Q37522557 | Complement related kidney diseases: Recurrence after transplantation |
| Q47108030 | Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways |
| Q58120548 | Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in and recurrent diseases |
| Q85950139 | Curcumin alleviates immune-complex-mediated glomerulonephritis in factor-H-deficient mice |
| Q34574482 | Current concepts in C3 glomerulopathy |
| Q34465747 | Defective complement inhibitory function predisposes to renal disease |
| Q37286653 | Dense deposit disease and C3 glomerulopathy |
| Q41377869 | Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation |
| Q50025267 | Drug-Induced Pseudoallergy: A Review of the Causes and Mechanisms |
| Q35597310 | Eculizumab and recurrent C3 glomerulonephritis |
| Q59273614 | Eculizumab in dense-deposit disease after renal transplantation |
| Q40865063 | Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy |
| Q36438860 | Kidney diseases caused by complement dysregulation: acquired, inherited, and still more to come |
| Q36509318 | Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency |
| Q27008508 | Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion |
| Q64039347 | Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations |
| Q34146380 | New insights into disease-specific absence of complement factor H related protein C in mouse models of spontaneous autoimmune diseases |
| Q38048606 | Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. |
| Q89080771 | Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily |
| Q38118454 | Properdin in complement activation and tissue injury |
| Q38088187 | Recent insights into C3 glomerulopathy |
| Q26741542 | Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN |
| Q35532337 | Regulating complement in the kidney: insights from CFHR5 nephropathy |
| Q55710477 | Retinal Basal Laminar Deposits in Complement fH/fP Mouse Model of Dense Deposit Disease. |
| Q43162540 | Role of Factor H and Related Proteins in Regulating Complement Activation in the Macula, and Relevance to Age-Related Macular Degeneration. |
| Q37260204 | Soluble CR1 therapy improves complement regulation in C3 glomerulopathy |
| Q37275993 | The incidence of possible causes of membranoproliferative glomerulonephritis: a single-center experience |
| Q38062343 | The renal biopsy in the genomic era. |
| Q89166249 | Timing and mechanism of conceptus demise in a complement regulatory membrane protein deficient mouse |
| Q48252388 | Treating C3 glomerulopathy with eculizumab. |
Search more.